Stocks and Investing
Stocks and Investing
Thu, December 17, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, December 16, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Jeffrey Hung Maintained (ACAD) at Buy with Increased Target to $60 on, Dec 16th, 2020
Jeffrey Hung of Morgan Stanley, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $58 to $60 on, Dec 16th, 2020.
Jeffrey has made no other calls on ACAD in the last 4 months.
There is 1 other peer that has a rating on ACAD. Out of the 1 peers that are also analyzing ACAD, 0 agree with Jeffrey's Rating of Hold.
This is the rating of the analyst that currently disagrees with Jeffrey
- Danielle Brill of "Raymond James" Upgraded from Buy to Strong Buy and Held Target at $65 on, Monday, November 16th, 2020
Contributing Sources